Live inFranceBelgiumNextSpain
Ask. Cite. Verify.
The European peer-review engine.
Search peer-reviewed medical literature with a clinical question. Get a cited summary where every claim is anchored to a peer-reviewed paper you can open and audit in one click.
Aligned with national guidelines
- HAS(France)
- KCE(Belgium)
- NICE
- EMA
Live demo
Watch a real literature query resolve in seconds.
This is the actual product, not a marketing reel. Every reference is a real peer-reviewed paper. Click any citation pill in your own query above to flash its source.
GLP-1 agonists vs SGLT2 inhibitors in T2DM with established cardiovascular disease, what does the recent literature show?
Synthesised in 4.2s · 5 European sources
In patients with T2DM and established atherosclerotic cardiovascular disease, trials show both GLP-1 RAs and SGLT2 inhibitors reduce major adverse cardiovascular events 1 2. Network meta-analyses report comparable HbA1c reduction at 52 weeks 3, with SGLT2is showing greater renal benefit and GLP-1 RAs greater weight reduction 4.
ESC/EASD 2023 guidance states choice may be guided by dominant comorbidity: heart failure or CKD favours an SGLT2i 5; atherosclerotic CVD without HF favours a GLP-1 RA 1. Clinical application remains the responsibility of the treating physician.
▼ Journal references · 5
- 1
GLP-1 receptor agonists in type 2 diabetes: meta-analysis of cardiovascular outcomes
The Lancet · 2023 · Marso SP, et al. EU
- 2
SGLT2 inhibitors and renal protection in patients with established cardiovascular disease
European Heart Journal · 2024 · Zinman B, et al. EU
- 3
Comparative effectiveness of GLP-1 RAs vs SGLT2is on HbA1c reduction at 52 weeks
Diabetologia · 2023 · Davies MJ, et al. EU
- 4
Network meta-analysis of glucose-lowering drugs in adults with type 2 diabetes
BMJ · 2024 · Palmer SC, et al.
- 5
Empagliflozin in heart failure with preserved ejection fraction
NEJM · 2022 · Anker SD, et al.
Quick-start
Start with a clinical topic.
Curated literature-search examples the system handles well. Sign in to run any of these, or anything else.
General medicine
Cardiology
Infectious disease
FAQ
Questions, answered.
How is this different from OpenEvidence?
eUvidence is a medical literature search tool built for European healthcare professionals: European peer-reviewed sources, European regulatory framing (EMA, NICE, HAS, KCE), GDPR-aligned data handling. We treat the EU not as a localisation, but as the editorial baseline.
Is this a clinical decision support tool?
No. eUvidence is a literature search and synthesis tool for verified healthcare professionals. It is not a medical device under EU MDR, has not been certified, and does not provide clinical decision support, diagnosis, or treatment recommendations. Results are summaries of published research. Clinical decisions remain the sole responsibility of the treating physician.
What happens to my queries?
Authenticated queries are stored against your account so you can revisit prior searches. Anonymous preview queries are never persisted. We never share queries with third parties; the underlying LLM provider's retention follows their published policy.
Which sources do you index?
Peer-reviewed journals indexed via PubMed and DOAJ, with priority weighting toward European publications and EU regulatory references (EMA, NICE, HAS, KCE). No preprints, no conference posters, no pharma marketing.
Try it on your hardest topic.
One literature query, no signup. If the citations don’t hold up, you owe us nothing.